Milestone Pharmaceuticals Inc (MIST)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $45.44M
Last updated: Nov 17, 2026 at 4:43 PM ET
Milestone Pharmaceuticals Inc (MIST) Statistics
Milestone Pharmaceuticals (MIST) has a market cap of $45.44M. Revenue grew 4812.96% over the last 12 months from the 12 months before. It kept -1844.80% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $45.44M |
|---|---|
| Latest price (Nov 17, 2026) | $0.41 |
Key Dates
The next earnings report is expected on Mar 18, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 18, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 9.7x. Its year-end P/S ranged from 3.5x to 109.6x from 2020 to 2025.
| P/S Ratio | 9.7x |
|---|---|
| Forward P/S | 11.9x |
Price Statistics
The stock is down 79.34% over 52 weeks and trades 46.75% below its 50-day average.
| Beta (1Y) | 2.80 |
|---|---|
| 52-Week Change | -79.34% |
| 1-Month Change | -40.98% |
| 3-Month Change | -61.74% |
| 6-Month Change | -71.10% |
| 5-Year Change | -87.03% |
| Total Return (1Y) | -79.34% |
| Total Return (3Y CAGR) | -42.72% |
| Total Return (5Y CAGR) | -42.09% |
| Max Drawdown (1Y) | -87.63% |
| Max Drawdown (3Y) | -89.23% |
| Sharpe Ratio (1Y) | -2.03 |
| Correlation with SPY (1Y) | 0.44 |
| 50-Day Average | $0.77 |
| 200-Day Average | $1.29 |
| 52-Week Range | $0.36 to $3.06 |
| RSI (14 Days) | 29.3 |
| Average Volume (20 Days) | 2.05M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.27x current liabilities.
| Current Ratio | 6.27x |
|---|---|
| Quick Ratio | 6.01x |
| Interest Coverage | -7.62x |
Returns and Efficiency
Return on invested capital is -133.93% over the last 12 months, against a 5-year average of -49.35%.
| Return on Assets (ROA) | -60.16% |
|---|---|
| Return on Invested Capital (ROIC) | -133.93% |
| Return on Capital Employed (ROCE) | -66.90% |
| ROA (5Y Average) | -60.80% |
| ROIC (5Y Average) | -49.35% |
| Asset Turnover | 0.04x |
| Inventory Turnover | 0.07x |
| Receivables Turnover | 1.35x |
| Cash Conversion Cycle | -2823 days |
Scores
MIST has an Altman Z-Score of -5.04, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -5.04 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $5.31M over the last 12 months.
| Revenue | $5.31M |
|---|---|
| Revenue Growth (YoY) | +4812.96% |
| Gross Profit | $4.93M |
| Operating Income | -$91.60M |
| Pretax Income | -$97.89M |
| Net Income | -$97.89M |
| EBITDA | -$90.93M |
| EBIT | -$91.60M |
| Reported EPS (TTM) | -$0.74 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $144.47M |
|---|---|
| Total Debt | $60.25M |
| Net Cash | $84.22M |
| Net Cash Per Share | $0.68 |
| Working Capital | $135.82M |
| Shareholder Equity | -$6.22M |
| Total Assets | $162.69M |
| Total Liabilities | $168.91M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $358.00K of capital spending, operating cash flow left -$77.14M of free cash flow.
| Operating Cash Flow | -$76.78M |
|---|---|
| Capital Expenditures | $358.00K |
| Free Cash Flow | -$77.14M |
| FCF Per Share | -$0.62 |
| Depreciation and Amortization | $673.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1726.39%.
| Gross Margin | 93.01% |
|---|---|
| Operating Margin | -1726.39% |
| Pretax Margin | -1844.80% |
| Net Margin | -1844.80% |
| EBITDA Margin | -1713.70% |
| EBIT Margin | -1726.39% |
| FCF Margin | -1453.86% |
Growth
Revenue fell 32.38% a year over 3 years.
| Revenue Growth (3Y CAGR) | -32.38% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -0.29% |
| Tangible Book Per Share Growth (2Y CAGR) | -0.29% |
Dividends and Yields
MIST does not pay a dividend. Its free cash flow yield is -149.96%.
| FCF Yield | -149.96% |
|---|---|
| Buyback Yield | -49.62% |
| Shareholder Yield | -49.62% |
Peer Position
Against 5 similar companies, MIST has the 5th highest P/S.
P/S RatioPeer median 16.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 9.7x vs 16.9x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +4812.96% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 256.14% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +256.14% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MIST
What is MIST's market cap?
Milestone Pharmaceuticals has a market cap of $45.44M.
How many shares of MIST are outstanding?
Milestone Pharmaceuticals has 124.50M shares outstanding. The count is up 29.02% from a year earlier.
Does MIST pay a dividend?
No. Milestone Pharmaceuticals does not pay a dividend.
How much debt does MIST have?
Milestone Pharmaceuticals has $60.25M of total debt and $144.47M of cash and equivalents, a net cash position of $84.22M.
MIST pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors